<DOC>
	<DOCNO>NCT00991107</DOCNO>
	<brief_summary>The objective study evaluate safety tolerance 20 mg ( 10 mg BID ) HE3286 administer orally 28 day obese insulin-resistant adult subject , assess activity HE3286 insulin sensitivity hepatic glucose production obese insulin-resistant adult subject .</brief_summary>
	<brief_title>A Study Safety , Tolerance Assessment HE3286 Insulin Sensitivity Hepatic Glucose Production</brief_title>
	<detailed_description>Hollis-Eden Pharmaceuticals , Inc. develop new class therapeutic treatment Type 2 diabetes mellitus ( T2DM ) . The investigational drug , HE3286 , synthetic analog naturally occur hormone potentially new mechanism action may improve current therapeutic option available T2DM patient . The glucose clamp gold standard measurement insulin sensitivity . Given observed activity HE3286 reduce insulin resistance impair glucose intolerant subject type 2 diabetic patient , necessary evaluate physiological site action ( i.e . liver vs. skeletal muscle ) HE3286 order understand mechanism action design future clinical trial .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Male female subject 1865 year age Body Mass Index ( BMI ) least 29 kg/m2 35 kg/m2 female 37 kg/m2 male Subject fast blood glucose level &lt; 126 mg/dL Screening Subject 2 hour postprandial ( follow 75 gram glucose administration ) blood glucose 140200 mg/dL Screening Subject fast plasma insulin &gt; =10 Î¼U/mL Subject history clinically significant cardiovascular disease ( include coronary artery disease ) , clinically significant hepatic , respiratory renal abnormality , clinically significant endocrine disorder ( include history diabetes ) ; clinically significant neurological psychiatric condition ; Subject clinically significant abnormality laboratory result screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>phase I</keyword>
	<keyword>safety</keyword>
	<keyword>tolerance</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>obese</keyword>
</DOC>